laparoscopic sleeve gastrectomy. Acquired absence of stomach [part of]
Conditions
Interventions
Intervention 1: Intervention group 1: Group (A) patients, after induction, 0.05 mg of haloperidol per kilogram (maximum dose of 30 mg) will be injected intravenously within 5 minutes. Intervention 2:
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Informed consent All patients who are candidates for LSG surgery ASA Class I and II between 18 and 60 years old
Exclusion criteria
Exclusion criteria: Patients with an underlying disease that is not currently under control. Patients who have a history of allergy to haloperidol or ondansetron. Patients who have a history of alcohol consumption, use of antidepressants and drug addiction (if they become symptomatic by not taking) pregnant women Lactating women People suffering from anxiety disorders, restlessness, tremors, convulsions, tinnitus Cases in which the surgeon decides to change the surgical procedure for any reason during the operation Patients who have a history of bradycardia, hypotension, cardiovascular collapse and respiratory arrest. Patients who have used an anti-nausea and vomiting agent within 24 hours before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea and vomiting. Timepoint: Every 15 minutes in recovery and every hour in the ward. Method of measurement: They will be evaluated based on VAS or Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli karami
Shiraz University of Medical Sciences
Outcome results
None listed